(AOF) – Medincell announced an agreement with the American AbbVie to co-develop and market up to six products in different therapeutic areas and indications. The biotech specialist in long-acting injectable drugs specifies that it will use its technological platform for the formulation of these therapies and that it will be in charge of formulation activities, preclinical studies, including CMC (Chemistry, Manufacturing) support activities. , and Controls), to bring candidates to the clinical stage.
AbbVie will finance and lead the clinical development of each program and will be responsible for regulatory approval, manufacturing and commercialization.